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Choosing Wisely Canada: The Canadian 
College of Medical Geneticists’ (CCMG) 
list of five items physicians and patients 
should question
Elaine Goh,1 Andrea Guerin,2 Joanna Lazier,3 
Sharan Goobie,4 Tanya N Nelson,5,6 Ron Agatep,7 Victoria Mok Siu,8 
Karen Y Niederhoffer,3 Julie Richer9
Choosing Wisely Canada aims to reduce 
patient harm by promoting discussion and 
awareness of unnecessary tests, proce-
dures and treatments. Organised by Cana-
dian physicians and the Canadian Medical 
Association,1 it is modelled after the 
American Choosing Wisely campaign.2 
The concept of ‘Choosing Wisely’ is now 
an international effort, across more than 
15 countries.1
The advances in genome sequencing 
technology have allowed for increased 
diagnostic yield while unmasking 
secondary findings or information of 
limited clinical utility.3 These findings 
may contribute to further unnecessary 
diagnostic testing, lifelong surveillance 
for low-risk sequelae and side effects of 
preventative treatment in healthy indi-
viduals, all of which may have economic 
consequences.3 Therefore, recommenda-
tions by genetics professionals to improve 
health and decrease costs are needed.
The Canadian College of Medical 
Geneticists (CCMG) is the national organ-
isation that establishes Canadian profes-
sional and ethical standards for medical 
genetics services. The CCMG through the 
leadership of the Ethics, Education, and 
Public Policy Committee (E2P2), under-
took an iterative process to formulate 
five items physicians and patients should 
question in medical genetics as part of 
Choosing Wisely Canada.
The initial statements (Summer 2015) 
were generated by a subcommittee of 
E2P2. Seven statements with the option 
for additions were presented in a pilot 
survey at the 2015 CCMG annual 
conference. For reference, the five 
statements from the American Choosing 
Wisely campaign were also provided.4 
After feedback, the statements from the 
pilot survey were modified or replaced 
by new ones and distributed to the 
entire CCMG membership (n=318) by 
electronic survey (SurveyMonkey, San 
Mateo, California, USA) in March 2016 
for ranking. Answers were weighted, and 
the five top statements were selected. 
The results of statement ranking by 
53/318 (17%) members responding to 
the electronic survey can be found in 
table 1. The top five statements chosen 
for literature review are bolded.
E2P2 reviewed the literature, gener-
ated a rationale for each statement and 
presented these orally during the 2016 
CCMG annual meeting for comment. 
Following revision, statements and their 
rationale were posted for comment 
online for 1 month with one reminder 
email sent to the membership. E2P2 
reviewed comments and edited state-
ments prior to submission to the 151 
Choosing Wisely Society Leads from 
other specialties (Fall 2016). Comments 
were received and addressed, including 
a change from ‘non-invasive prenatal 
testing’ (NIPT) to ‘non-invasive 
prenatal detection of fetal aneuploidies 
by cell-free DNA’ and keeping the term 
‘children’ rather than ‘minors’ despite 
objection, to be consistent with other 
society statements.5 6
The final statements as below were 
submitted to the Choosing Wisely Canada 
organisation on 1 January 2017:
Don’T use non-invasive prenaTal 
DeTeCTion of feTal aneuploiDies by 
Cell-free Dna as a DiaGnosTiC TesT
Non-invasive prenatal detection of fetal 
aneuploidies by cell-free DNA, also 
called non-invasive prenatal testing and 
non-invasive prenatal screening, is a 
method of non-invasive fetal DNA testing 
done through a maternal blood sample. 
NIPT testing for common aneuploidies, 
microdeletions and sex chromosome 
disorders7 is clinically available to patients 
in Canada. NIPT is a highly sensitive and 
specific screening test but is not diag-
nostic.8 Even in high-risk populations, 
there can be false-positive NIPT results. 
Genetic counselling, along with confirma-
tory testing via amniocentesis or chorionic 
villus sampling, should be done prior to 
using the result to impact management of 
a pregnancy.
Don’T Make MeDiCal DeCisions 
baseD on resulTs of DireCT To 
ConsuMer GeneTiC TesTinG WiThouT 
a Clear unDersTanDinG of The 
liMiTaTions anD valiDiTy of The TesT
Three types of potentially medi-
cally relevant direct to consumer genetic 
testing (DTC-GT) are available: (1) assess-
ment of risk for common multifactorial 
diseases (eg, diabetes); (2) targeted muta-
tion analysis for single gene disorders; and 
(3) sequencing. Some DTC-GT companies 
state that they do not guarantee the accu-
racy or reliability of their tests. Many of 
the significant genetic risk and protective 
factors for multifactorial conditions have 
not been identified. This leads to greatly 
divergent risk interpretations between 
companies, even when performed on the 
same individual.9 For targeted mutation 
analysis and sequencing, the specific test 
may not include all clinically relevant 
genes or mutations, resulting in false reas-
surance.10 Genetic changes that are only 
weakly associated with disease may be 
reported, leading to anxiety or inappro-
priate additional testing. When making 
medical decisions based on results of 
genetic testing, the test should meet the 
recommendations made by the CCMG 
in 2012.11 Not all DTC-GT meet these 
recommendations.
Don’T orDer a ChroMosoMe 
analysis by DoinG a karyoType 
for inDiviDuals WiTh inTelleCTual 
DisabiliTy/DevelopMenTal Delay of 
unknoWn aeTioloGy
Microarray is the first-line test for indi-
viduals with intellectual disability/
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developmental delay without a recognis-
able syndrome.12 Indeed, a microarray has 
a much higher detection rate (15%–20%) 
compared with a karyotype (3%–4%) 
in individuals presenting for this clin-
ical indication.13 A karyotype remains 
important in limited clinical situations 
where a specific numerical or structural 
chromosomal syndrome, such as Down 
syndrome, is suspected.
Don’T orDer Whole exoMe 
sequenCinG (Wes) prior To GeneTiC 
CounsellinG
WES is a powerful test for individuals 
suspected of having an underlying genetic 
diagnosis. However, WES increases the 
likelihood of unexpected findings, which 
may or may not be clinically significant. 
Furthermore, due to methodological 
limitations, WES may not always be the 
correct test to order as WES will not 
detect all genetic causes of disease (eg, 
it will not detect chromosomal struc-
tural differences).14 Both informative 
and uninformative results can lead to 
complex patient and family psychosocial 
repercussions15 and could impair future 
insurability. Genetic counselling facili-
tates informed decision making. Given 
complexity of results, WES should only 
be ordered after counselling by a quali-
fied healthcare provider.
Don’T orDer Carrier TesTinG in 
ChilDren
Carrier testing is primarily useful in the 
reproductive period to determine the risk 
of an individual having a child affected 
by the condition for which testing is 
being considered.5 Knowing that a child 
is a carrier of an X-linked or autosomal 
recessive condition usually does not alter 
medical care in the paediatric years since 
most carriers are unaffected. Thus, in most 
situations, there is not a medical indica-
tion for carrier testing in a child.6 Under-
taking carrier testing of a child violates the 
right of the child to make his or her own 
decision about testing and could impair 
future insurability. An exception could be 
made for a mature adolescent who may be 
able to understand the reproductive impli-
cations of carrier testing after appropriate 
genetic counselling.
This expert CCMG consensus reflects 
Choosing Wisely statements covering a 
broad range of genetic issues relevant 
to Canadians. As no demographic infor-
mation was collected from the member-
ship survey, it is not known whether the 
responses were representative of both 
laboratory geneticists and clinical geneti-
cists, but there were equal opportunities 
for both to provide feedback.
It is interesting that only one state-
ment regarding WES is similar to the 
American recommendations.4 While the 
American version was specific about 
recommending informed consent, partic-
ularly around secondary findings, the 
Canadian version recommends genetic 
counselling, which is more generalised 
and would encompass informed consent 
as part of the counselling process. 
Three of the American statements target 
specific genetic tests (APO-E, MTHFR 
and HFE).4 In Canada, some of these 
tests are not routinely offered or covered 
by provincial healthcare. It is possible 
that the perspective taken in generating 
these recommendations in the USA 
versus Canada differs based on the target 
audience requesting the tests, the health-
care systems or the practice differences 
between the two countries. Regardless of 
the reason, this report suggests that there 
is value in determining country-specific 
recommendations. As technology and 
knowledge advance, these statements 
may need to be revised.
As the goal of the Choosing Wisely 
campaign is to reduce patient harm by 
generating greater awareness of respon-
sible use of testing and procedures, these 
five recommendations represent the start 
of a dialogue that will hopefully optimise 
utilisation of resources related to medical 
genetics.
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